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Abstract. An easily accessible prolinol derived ligand, (S)-
bis(3,5-bis(trifluoromethyl)phenyl)(pyrrolidin-2-
yl)methanol, has been efficiently applied in the catalytic 
enantioselective addition of terminal alkynes to cyclic 
imines using dimethylzinc (Me2Zn) under mild reaction 
conditions. The developed catalytic system led to chiral 
propargylic sulfamidates with high yields (up to 97%) and 
excellent enantioselectivities (up to 97% ee). 
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The enantioselective alkynylation of imines is one of 
the most useful carbon-carbon bond-forming reactions 
for the preparation of chiral propargylic amines,[1] 
which are versatile building blocks for the synthesis of 
fine chemicals, pharmaceuticals,[2] agrochemicals[3] and 
natural products.[4] Recently, a large number of catalytic 
enantioselective methodologies have been described for 
the asymmetric addition of terminal alkynes to acyclic 
imines (Scheme 1).[5] However, the enantioselective 
alkynylation of cyclic imines is less studied despite their 
great potential for the synthesis of chiral polyfunctional 
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Scheme 1. Enantioselective alkynylation of imines 
For example, different methodologies have been 
described for the enantioselective alkynylation of six 
membered cyclic N-acyl trifluoromethyl activated 
imines,[7] seven membered cyclic imines such as 
dibenzoxazepines,[8] and cyclic iminium ions derived 
from pyridines,[9] tetrahydroisoquinolines,[10] 
isoquinolines[9b] or quinolines.[9b,11] Another remarkable 
type of cyclic imines are benzoxathiazine 2,2-dioxides, 
which  have proven to be versatile building blocks in 
asymmetric synthesis and in the construction of chiral 
benzofused cyclic sulfamidate heterocycles by the 
addition of organometallic nucleophiles.[12] 
Nevertheless, the alkynylation of benzoxathiazine 2,2-
dioxides that affords chiral propargylic sulfamidates has 
been scarcely studied.[13] 
Sulfamidates are an interesting class of amine 
derivatives present in some pharmaceuticals and 
biological active compounds [14] and they also play an 
important role as building blocks for organic 
synthesis.[15] For this reason, we focused our efforts in 
the preparation of chiral propargylic sulfamidates by the 
direct addition of terminal alkynes to cyclic 
benzoxathiazine 2,2-dioxides. We have recently 
reported this reaction by using dimethylzinc and (R)-
VAPOL as catalyst.[13] However, the reaction did not 
proceeded with high enantioselectivities (56 to 87% ee) 
and only a limited number of cyclic imines and aliphatic 
alkynes were tolerated. In addition, we were not 
satisfied with the use of the commercially available but 
expensive (R)-VAPOL.[16] We believe that the success 
of an enantioselective catalytic process also implies the 
utilization of easily accessible and inexpensive ligands. 
Therefore, we decided to continue studying the 
alkynylation of benzoxathiazine 2,2-dioxides in order to 
develop an enhanced methodology by using a more 
simple and economical ligand that could afford better 
enantioselectivities (Scheme 2). For this purpose, we 
thought in the use of chiral amino alcohols as chiral 
ligands. 
Chiral amino alcohols have been used in several zinc 
mediated alkynylation reactions of aldehydes,[17] 
ketones[18] and imines,[19] because amino alcohol-Zn 
catalytic systems are particularly noteworthy in terms of 
its operational simplicity and mild reaction conditions. 
However, chiral amino alcohols have been rarely used 
in catalytic enantioselective alkynylation of cyclic 
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imines. Among the chiral amino alcohols described in 
the literature, chiral diarylprolinols are a very 
convenient class of ligands for asymmetric catalysis as 
they can be easily prepared from proline and, in some 
cases, are commercially available. Therefore, we 
decided to apply this kind of ligands in enantioselective 
alkynylation reactions. Herein, we report a highly 
efficient catalytic system for the alkynylation of cyclic 
benzoxathiazine 2,2-dioxides using a diarylprolinol-
Zn(II) complex as catalyst, affording the corresponding 
chiral propargylic sulfamidates with higher 
enantiomeric excesses than with the previously 
described catalytic system.[13] 
 
 
Scheme 2. Enantioselective alkynylation of cyclic 
benzoxathiazine 2,2-dioxides. 
We initiated our studies by evaluating the addition of 
phenyl-acetylene (2a) to cyclic benzo[e][1,2,3]-
oxathiazine 2,2-dioxide (1a) in the presence of a series 
of diarylprolinol-Zn(II) complexes.  A 1.2 M Me2Zn 
solution in toluene (4 eq.) was added dropwise to a 
solution of ligand L (0.2 eq.) and phenylacetylene (7 
eq.) in toluene at room temperature. After stirring for 
0.5 h the reaction mixture, a solution of the cyclic imine 
1a in toluene was added. Under these reaction 
conditions, several diarylprolinol-type ligands L1–L4 
were tested (Table 1, entries 1–4). When ligands L1, L2 
and L4 were used, the corresponding chiral propargylic 
sulfamidates 3aa were obtained with good yields (80-
86%) but moderate enantioselectivities (53-59% ee). 
Gratefully, when (S)-bis(3,5-
bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol 
(L3) was utilized as a ligand, product 3aa was gained 
with 90% yield and high enantioselectivity (93% ee) 
(entry 3, Table1). However, we observed the formation 
of product 4, obtained by the addition of Me2Zn to the 
cyclic imine 1a. Although the ratio between product 
3aa:4 was not significant (1:0.05, determined by 1H 
NMR), we wanted to avoid the formation of product 4. 
Therefore, different solvents such as CH2Cl2, 
ClCH2CH2Cl, Et2O and MTBE were tested (entries 5-8, 
Table 1). Utilization of chlorinated solvents resulted in 
a decreased enantioselectivity of the reaction, whereas 
the use of ethereal solvents led to high enantiomeric 
excess, but had a negative influence on the yield. Et2Zn 
was also tested as a zinc reagent (entry 9, Table 1); 
however, higher amount of the addition of Et2Zn to the 
imine 1a was observed. In order to avoid the formation 
of this undesired product, we generated the chiral zinc 
complex at higher temperature, obtaining product 3aa 
with higher yield and selectivity (entry 10, Table 1). 
When we performed the reaction at 0 ºC (entry 12, Table 
1), we could increase the enantiomeric excess to 97%, 
without compromising the yield (96%). Finally, 
lowering the amount of Me2Zn to 3 equivalents or the 
ligand amount to 10 mol% had a detrimental effect on 
the enantioselectivity (entries 13 and 14, respectively).   
  
Table 1. Optimization of the reaction conditions.a 
 








1 L1 (20) toluene rt 80 1:0 53 
2 L2 (20) toluene rt 85 1:0 57 
3 L3 (20) toluene rt 90 1:0.05 93 
4 L4 (20) toluene rt 86 1:0 59 
5 L3 (20) CH2Cl2 rt 84 1:0 87 
6 L3 (20) DCE rt 90 1:0.03 83 
7 L3 (20) Et2O rt 57 1:0.01 93 
8 L3 (20) MTBE rt 70 1:0.08 91 
9e L3 (20) toluene rt 72 1:0.3f 87 
10g L3 (20) toluene rt 96 1:0.02 93 
11g L3 (20) toluene 0 98 1:0.03 96 
12h L3 (20) toluene 0 96 1:0.01 97 
13h,i L3 (20) toluene 0 97 1:0.03 95 
14h L3 (10) toluene 0 87 1:0.05 86 
a) Reaction conditions: 1a (0.1 mmol), 2a (0.7 mmol), 1.2 M 
Me2Zn in toluene (0.4 mmol) and ligand L (x mol%) in 1.5 
mL of solvent. b) Isolated yield after column chromatography. 
c) Determined by 1H NMR. d) Determined by HPLC using 
chiral stationary phase. E) Et2Zn (0.4 mmol) was used. f) The 
ethylation product was observed. g) The chiral zinc complex 
was formed at 70 ºC for 0.5 h. h) The chiral zinc complex was 
formed at 70 ºC for 1 h. i) 3 eq. of Me2Zn were used.  
With the optimized reaction conditions in our hands 
(entry 12, Table 1), we turned our attention to 
stablishing the scope with respect to both the cyclic 
imines 1 and alkynes 2 (Scheme 3 and 4). First, we 
explored the reaction with several terminal alkynes 
bearing different electronic and steric demands 
(Scheme 3). The electronic properties of the aromatic 
ring of the terminal alkynes affected slightly the 
enantioselectivity of the reaction. The presence of a 
methoxy group in the para position resulted in the 
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formation of 3ab with excellent yield (96%) and 
excellent enantioselectivity (97% ee). The use of para-
chloro-ethynylbenzene (2c) gave the corresponding 
product 3ac with 97% yield and high enantiomeric 
excess (90% ee). An alkyne bearing a substituent in 
meta gave 3ad in excellent yield and 91% ee. 
Remarkably, when the alkynylation was performed with 
an aromatic alkyne having a methoxy group in the ortho 
position (2e), the chiral sulfamidate 3ae was afforded 
with excellent enantioselectivity (95% ee). 
Heteroaromatic alkynes (2f and 2g) were also suitable 
nucleophiles for this reaction, and the corresponding 
chiral products 3af and 3ag were obtained with 
enantioselectivities up to 94% ee. Finally, in order to 
fully study the scope of the reaction, aliphatic alkynes 
(2h–2l) were evaluated. The reactions were performed 
at room temperature since this allowed to obtain high 
conversions and good enantioselectivities. When but-3-
yn-1-ylbenzene (2h) or hex-1-yne (2i) were used, the 
corresponding products were obtained with a lower 
enantiomeric excess (80% ee). The more hindered 3,3-
dimethylbut-1-yne 2j gave better enantioselectivity 
(88% ee). Alternatively, employment of cyclic terminal 
alkynes such as ethynylcyclopropane (2k) and 
ethynylcyclopentane (2i) led to the corresponding 
sulfamidates 3ak and 3al in high yields and 
enantiomeric excesses over 90%. 
 
Scheme 3. Scope of the alkynylation of cyclic imines: 1 (0.1 
mmol), 2a (0.7 mmol), 1.2 M Me2Zn in toluene (0.4 mmol) 
and L3 (20 mol%) in toluene at 0 ºC. Isolated yields after 
column chromatography. Enantiomeric excesses were 
determined by HPLC using chiral stationary phase.  
After studying the reaction with different alkynes, we 
focused our attention in the use of various 
benzoxathiazine 2,2-dioxides 1 (Scheme 4).[20] Both 
electron-donating and electron-withdrawing groups 
with different steric demand in the 6 position (3ba-3ea) 
were well tolerated, obtaining high yields and good to 
high enantiomeric excesses (80% to 96% ee). A cyclic 
imine bearing a substituent in the 8 position gave 
product 3fa in 85% yield and 94% ee. However, the 
presence of a methoxy group in the 5 position led to a 
decrease in the enantioselectivity of the reaction (3ga, 
76% yield, 70% ee). Remarkably, the sterically 
hindered cyclic imine 1h with two tBu substituents was 
a suitable substrate for the alkynylation reaction, 
affording the desired product 3ha with excellent 
enantiomeric excess (97% ee). An imine containing a 
naphthyl group could also be applied in the reaction 
giving 3ia in good yield (84%) and enantioselectivity 
(86% ee). 
 
Scheme 4. Scope of the alkynylation of cyclic imines: 1 (0.1 
mmol), 2a (0.7 mmol), 1.2 M Me2Zn in toluene (0.4 mmol) 
and L3 (20 mol%) in toluene at 0 ºC. Isolated yields after 
column chromatography. Enantiomeric excesses were 
determined by HPLC using chiral stationary phase. [a] 1:0.01 
ratio of alkynylation:methylation product.  
Furthermore, we performed several synthetic transformations 
with the chiral propargylic sulfamidate 3aa (Scheme 5). By 
hydrogenation of the triple bond, compound 4 could be 
prepared (81% yield), which by treatment with LiAlH4, 
followed by a Boc protection, gave the corresponding  
product 5 (78% yield) with a slightly decrease in the optical 
purity of 3aa. 
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Scheme 5. Synthetic transformations of product 3aa.  
A plausible mechanism for the enantioselective 
alkynylation reaction using a prolinol-derived ligand is 
shown in Scheme 6. Similarly to the alkylation with 
Me2Zn or Et2Zn catalyzed by amino alcohols, complex 
A is generated by the reaction of ligand L3 and Me2Zn, 
which is in equilibrium with the more stable dimer 
complex B.[21,22] Complex A is also in equilibrium with 
complex C, where a methyl alkynyl organozinc species 
has coordinated to the oxygen atom of complex A. This 
is followed by the coordination of benzoxathiazine 2,2-
dioxide to the Zn atom chelated by the amino alcohol, 
because to its higher Lewis acidity among both Zn 
atoms, generating complex D. It is known that, in 
alkylzinc acetylides,[23] the alkynyl moiety is more 
reactive than the alkyl one and, therefore, the acetylide 
is transferred to the Re face of the cyclic imine 
generating the chiral propargylic zinc sulfamidate 
complex E. Once the sulfamidate is released to further 
afford the final product 3, another methyl alkynyl 
organozinc specie is coordinated to the zinc alkoxide 
monomer regenerating complex C. 
 
 
Scheme 6. Plausible mechanism of the enantioselective 
alkynylation using a prolinol-type ligand. 
In conclusion, we have successfully developed a highly 
enantioselective alkynylation of benzo[e][1,2,3]-
oxathiazine 2,2-dioxides catalyzed by chiral 
diarylprolinol-Zn(II) complexes. The corresponding 
chiral propargylic sulfamidates are obtained with good 
yields (up to 97%) and good to excellent 
enantioselectivities (up to 97% ee). This methodology 
features the use of economical and commercially 
available (S)-bis(3,5-
bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol 
L3  as a chiral ligand for the enantioselective 
alkynylation of benzoxathiazine 2,2-dioxides under 
mild reaction conditions and provides access to highly 
optically pure chiral propargylic sulfamidates, 
important chiral building blocks in organic synthesis. 
 
Experimental Section 
General Procedure for the Enantioselective Alkynylation 
Reaction 
A 1.2 M Me2Zn solution in toluene (0.400 mmol) was added 
dropwise to a solution of L3 (0.020 mmol) and alkyne 2 
(0.700 mmol) in toluene (0.3 mL) and was heated to 70 °C 
under nitrogen atmosphere. After stirring for 1 hour, the 
solution was cooled to 0 °C and a solution of benzoxathiazine 
2,2-dioxide 1 (0.100 mmol) in toluene (1.0 mL) was added 
via syringe at 0 °C. The reaction was stirred at this 
temperature until TLC analysis indicated full conversion of 
the starting material. The reaction was quenched with NH4Cl 
(10 mL), extracted with dichloromethane (3x15 mL), washed 
with brine (10 mL) and dried over MgSO4. After the solvent 
was removed under reduced pressure, purification by flash 
chromatography on silica gel afforded compound 3. 
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